Abstract PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration ...
The combination therapy is the first FDA approved for the mobilization of hematopoietic stem cells prior to autologous transplantation in patients with multiple myeloma. The FDA approved motixafortide ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results